Bicycle Therapeutics is developing a brand new class of small, chemically synthesised medicines, called Bicycles.
To redefine what’s possible for people with cancer and other diseases.
We were founded in 2009 based on innovative science conducted in the laboratory of Sir Greg Winter, a pioneer in monoclonal antibodies, to translate our first-in-class Bicycles into transformative medicines for life-altering diseases. We are a transatlantic company, with headquarters in Cambridge, U.K., and many key functions and members of our leadership team located in the biotech hub of Boston, Mass.
We are experienced leaders who are driven by a common goal – to develop a novel class of therapies for diseases where existing treatment options are limited.